Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis
PURPOSENeoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy is the gold standard for treating patients with higher risk early triple-negative breast cancer (TNBC); however, in some cases, these patients undergo surgery followed by chemotherapy-based anthracyclines and taxanes without ad...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-05-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729519589523456 |
|---|---|
| author | Hassan Abdelilah Tafenzi Farah Choulli Ismail Essaadi Rhizlane Belbaraka |
| author_facet | Hassan Abdelilah Tafenzi Farah Choulli Ismail Essaadi Rhizlane Belbaraka |
| author_sort | Hassan Abdelilah Tafenzi |
| collection | DOAJ |
| description | PURPOSENeoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy is the gold standard for treating patients with higher risk early triple-negative breast cancer (TNBC); however, in some cases, these patients undergo surgery followed by chemotherapy-based anthracyclines and taxanes without adhering to the guidelines.METHODSPatients with previously untreated stage I, II, and III TNBC who received adjuvant therapy with either doxorubicin and cyclophosphamide (AC) + docetaxel (AC-D), AC + weekly paclitaxel (AC-WP), epirubicin and cyclophosphamide (EC) + docetaxel (EC-D), or EC + WP (EC-WP); older than 18 years; and diagnosed between January 1st, 2011, and December 31st, 2022, were eligible for the study. Disease-free survival (DFS) is the primary reported end point. Overall survival (OS) and safety were the secondary end points.RESULTSWe included 272 female patients. At a prespecified event-driven data cutoff, with a median follow-up of 26.3 months, the 5-year DFS was 49% (95% CI, 38 to 63) in the AC-D group, 45% (95% CI, 29 to 70) in the AC-WP group, 73% (95% CI, 61 to 100) in the EC-D group, and 72% (95% CI, 44 to 100) in the EC-WP group (hazard ratio [HR], 0.2 [95% CI, 0.06 to 0.67]; P = .08). The 7-year OS was 52% (95% CI, 32 to 83) in the AC-D group, 88% (95% CI, 78 to 99) in the AC-WP group, 95% (95% CI, 88 to 100) in the EC-D group, and 83% (95% CI, 58 to 100) in the EC-WP group (HR, 0.19 [95% CI, 0.06 to 0.66]; P = .03). Most of the grade 3-4 adverse events occurred in the AC-D group, primarily neutropenia, nausea-vomiting, and alopecia.CONCLUSIONEC-D was linked to a slightly longer survival free of invasive, noninvasive, or distant disease and a significantly longer OS with fewer adverse events. Further studies are needed to confirm and establish long-term clinical benefits. |
| format | Article |
| id | doaj-art-0c53d692c79443df893e78a2c2ce2ee3 |
| institution | DOAJ |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-0c53d692c79443df893e78a2c2ce2ee32025-08-20T03:09:12ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-05-011110.1200/GO-24-00650Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective AnalysisHassan Abdelilah Tafenzi0Farah Choulli1Ismail Essaadi2Rhizlane Belbaraka3Medical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, MoroccoMedical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, MoroccoBiosciences and Health Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, MoroccoMedical Oncology Department, Mohammed VI University Hospital of Marrakech, Marrakech, MoroccoPURPOSENeoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy is the gold standard for treating patients with higher risk early triple-negative breast cancer (TNBC); however, in some cases, these patients undergo surgery followed by chemotherapy-based anthracyclines and taxanes without adhering to the guidelines.METHODSPatients with previously untreated stage I, II, and III TNBC who received adjuvant therapy with either doxorubicin and cyclophosphamide (AC) + docetaxel (AC-D), AC + weekly paclitaxel (AC-WP), epirubicin and cyclophosphamide (EC) + docetaxel (EC-D), or EC + WP (EC-WP); older than 18 years; and diagnosed between January 1st, 2011, and December 31st, 2022, were eligible for the study. Disease-free survival (DFS) is the primary reported end point. Overall survival (OS) and safety were the secondary end points.RESULTSWe included 272 female patients. At a prespecified event-driven data cutoff, with a median follow-up of 26.3 months, the 5-year DFS was 49% (95% CI, 38 to 63) in the AC-D group, 45% (95% CI, 29 to 70) in the AC-WP group, 73% (95% CI, 61 to 100) in the EC-D group, and 72% (95% CI, 44 to 100) in the EC-WP group (hazard ratio [HR], 0.2 [95% CI, 0.06 to 0.67]; P = .08). The 7-year OS was 52% (95% CI, 32 to 83) in the AC-D group, 88% (95% CI, 78 to 99) in the AC-WP group, 95% (95% CI, 88 to 100) in the EC-D group, and 83% (95% CI, 58 to 100) in the EC-WP group (HR, 0.19 [95% CI, 0.06 to 0.66]; P = .03). Most of the grade 3-4 adverse events occurred in the AC-D group, primarily neutropenia, nausea-vomiting, and alopecia.CONCLUSIONEC-D was linked to a slightly longer survival free of invasive, noninvasive, or distant disease and a significantly longer OS with fewer adverse events. Further studies are needed to confirm and establish long-term clinical benefits.https://ascopubs.org/doi/10.1200/GO-24-00650 |
| spellingShingle | Hassan Abdelilah Tafenzi Farah Choulli Ismail Essaadi Rhizlane Belbaraka Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis JCO Global Oncology |
| title | Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis |
| title_full | Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis |
| title_fullStr | Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis |
| title_full_unstemmed | Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis |
| title_short | Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis |
| title_sort | real world outcomes of combination anthracycline and taxane adjuvant therapies in early triple negative breast cancer a moroccan retrospective analysis |
| url | https://ascopubs.org/doi/10.1200/GO-24-00650 |
| work_keys_str_mv | AT hassanabdelilahtafenzi realworldoutcomesofcombinationanthracyclineandtaxaneadjuvanttherapiesinearlytriplenegativebreastcanceramoroccanretrospectiveanalysis AT farahchoulli realworldoutcomesofcombinationanthracyclineandtaxaneadjuvanttherapiesinearlytriplenegativebreastcanceramoroccanretrospectiveanalysis AT ismailessaadi realworldoutcomesofcombinationanthracyclineandtaxaneadjuvanttherapiesinearlytriplenegativebreastcanceramoroccanretrospectiveanalysis AT rhizlanebelbaraka realworldoutcomesofcombinationanthracyclineandtaxaneadjuvanttherapiesinearlytriplenegativebreastcanceramoroccanretrospectiveanalysis |